Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: Study protocol for a randomized controlled trial

Boadie W. Dunlop, Barbara O. Rothbaum, Elisabeth B. Binder, Erica Duncan, Philip D Harvey, Tanja Jovanovic, Mary E. Kelley, Becky Kinkead, Michael Kutner, Dan V. Iosifescu, Sanjay J. Mathew, Thomas C. Neylan, Clinton D. Kilts, Charles Nemeroff, Helen S. Mayberg

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Pharmacologic treatment options for posttraumatic stress disorder (PTSD) are limited in number and effectiveness. Medications currently in use to treat PTSD were originally approved based on their efficacy in other disorders, such as major depression. Substantial research in PTSD suggests that increased activity of corticotropin releasing hormone (CRH)-containing circuits are involved in the pathophysiology of the disease. This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD.Methods/design: Currently untreated adult women, ages 18 to 65 years, with a primary psychiatric diagnosis of PTSD of at least 3 months' duration, are being enrolled in a parallel-group, double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of GSK561679, a novel CRHR1 receptor antagonist. GSK561679 (or matching placebo) is prescribed at a fixed dose of 350 mg nightly for six weeks. The primary trial hypothesis is that GSK561679 will reduce symptoms of PTSD, as measured by the Clinician-Administered PTSD Scale (CAPS), significantly more than placebo after six weeks of treatment. Putative biological markers of PTSD which may influence treatment response are measured prior to randomization and after five weeks' exposure to the study medication, including: fear conditioning and extinction using psychophysiological measures; variants of stress-related genes and gene expression profiles; and indices of HPA axis reactivity. In addition, the impact of PTSD and treatment on neuropsychological performance and functional capacity are assessed at baseline and after the fifth week of study medication. After completion of the six-week double blind treatment period, subjects enter a one-month follow-up period to monitor for sustained response and resolution of any adverse effects.Discussion: Considerable preclinical and human research supports the hypothesis that alterations in central nervous system CRH neuronal activity are a potential mediator of PTSD symptoms. This study is the first to assess the efficacy of a specific antagonist of a CRH receptor in the treatment of PTSD. Furthermore, the biological and neuropsychological measures included in this trial will substantially inform our understanding of the mechanisms of PTSD.Trial registration: Clinicaltrials.gov Identifier: NCT01018992.Registered 6 November 2009. First patient randomized 14 January 2010.

Original languageEnglish
Article number240
JournalTrials
Volume15
Issue number1
DOIs
StatePublished - Jun 21 2014

Fingerprint

Post-Traumatic Stress Disorders
Randomized Controlled Trials
Corticotropin-Releasing Hormone
Placebos
Therapeutics
CRF receptor type 1
Corticotropin-Releasing Hormone Receptors
Random Allocation
Transcriptome
Research
Mental Disorders
Fear
Central Nervous System
Biomarkers
Depression
Safety

Keywords

  • Anxiety disorders
  • Clinical Research Protocol
  • CRH
  • Drugs
  • Fear conditioning
  • Fear-potentiated startle
  • HPA Axis
  • Investigational
  • Neuropsychological tests
  • Placebo
  • Psychophysiology

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder : Study protocol for a randomized controlled trial. / Dunlop, Boadie W.; Rothbaum, Barbara O.; Binder, Elisabeth B.; Duncan, Erica; Harvey, Philip D; Jovanovic, Tanja; Kelley, Mary E.; Kinkead, Becky; Kutner, Michael; Iosifescu, Dan V.; Mathew, Sanjay J.; Neylan, Thomas C.; Kilts, Clinton D.; Nemeroff, Charles; Mayberg, Helen S.

In: Trials, Vol. 15, No. 1, 240, 21.06.2014.

Research output: Contribution to journalArticle

Dunlop, BW, Rothbaum, BO, Binder, EB, Duncan, E, Harvey, PD, Jovanovic, T, Kelley, ME, Kinkead, B, Kutner, M, Iosifescu, DV, Mathew, SJ, Neylan, TC, Kilts, CD, Nemeroff, C & Mayberg, HS 2014, 'Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: Study protocol for a randomized controlled trial', Trials, vol. 15, no. 1, 240. https://doi.org/10.1186/1745-6215-15-240
Dunlop, Boadie W. ; Rothbaum, Barbara O. ; Binder, Elisabeth B. ; Duncan, Erica ; Harvey, Philip D ; Jovanovic, Tanja ; Kelley, Mary E. ; Kinkead, Becky ; Kutner, Michael ; Iosifescu, Dan V. ; Mathew, Sanjay J. ; Neylan, Thomas C. ; Kilts, Clinton D. ; Nemeroff, Charles ; Mayberg, Helen S. / Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder : Study protocol for a randomized controlled trial. In: Trials. 2014 ; Vol. 15, No. 1.
@article{3041011994614a0f854479ddfe8ff143,
title = "Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: Study protocol for a randomized controlled trial",
abstract = "Background: Pharmacologic treatment options for posttraumatic stress disorder (PTSD) are limited in number and effectiveness. Medications currently in use to treat PTSD were originally approved based on their efficacy in other disorders, such as major depression. Substantial research in PTSD suggests that increased activity of corticotropin releasing hormone (CRH)-containing circuits are involved in the pathophysiology of the disease. This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD.Methods/design: Currently untreated adult women, ages 18 to 65 years, with a primary psychiatric diagnosis of PTSD of at least 3 months' duration, are being enrolled in a parallel-group, double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of GSK561679, a novel CRHR1 receptor antagonist. GSK561679 (or matching placebo) is prescribed at a fixed dose of 350 mg nightly for six weeks. The primary trial hypothesis is that GSK561679 will reduce symptoms of PTSD, as measured by the Clinician-Administered PTSD Scale (CAPS), significantly more than placebo after six weeks of treatment. Putative biological markers of PTSD which may influence treatment response are measured prior to randomization and after five weeks' exposure to the study medication, including: fear conditioning and extinction using psychophysiological measures; variants of stress-related genes and gene expression profiles; and indices of HPA axis reactivity. In addition, the impact of PTSD and treatment on neuropsychological performance and functional capacity are assessed at baseline and after the fifth week of study medication. After completion of the six-week double blind treatment period, subjects enter a one-month follow-up period to monitor for sustained response and resolution of any adverse effects.Discussion: Considerable preclinical and human research supports the hypothesis that alterations in central nervous system CRH neuronal activity are a potential mediator of PTSD symptoms. This study is the first to assess the efficacy of a specific antagonist of a CRH receptor in the treatment of PTSD. Furthermore, the biological and neuropsychological measures included in this trial will substantially inform our understanding of the mechanisms of PTSD.Trial registration: Clinicaltrials.gov Identifier: NCT01018992.Registered 6 November 2009. First patient randomized 14 January 2010.",
keywords = "Anxiety disorders, Clinical Research Protocol, CRH, Drugs, Fear conditioning, Fear-potentiated startle, HPA Axis, Investigational, Neuropsychological tests, Placebo, Psychophysiology",
author = "Dunlop, {Boadie W.} and Rothbaum, {Barbara O.} and Binder, {Elisabeth B.} and Erica Duncan and Harvey, {Philip D} and Tanja Jovanovic and Kelley, {Mary E.} and Becky Kinkead and Michael Kutner and Iosifescu, {Dan V.} and Mathew, {Sanjay J.} and Neylan, {Thomas C.} and Kilts, {Clinton D.} and Charles Nemeroff and Mayberg, {Helen S.}",
year = "2014",
month = "6",
day = "21",
doi = "10.1186/1745-6215-15-240",
language = "English",
volume = "15",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder

T2 - Study protocol for a randomized controlled trial

AU - Dunlop, Boadie W.

AU - Rothbaum, Barbara O.

AU - Binder, Elisabeth B.

AU - Duncan, Erica

AU - Harvey, Philip D

AU - Jovanovic, Tanja

AU - Kelley, Mary E.

AU - Kinkead, Becky

AU - Kutner, Michael

AU - Iosifescu, Dan V.

AU - Mathew, Sanjay J.

AU - Neylan, Thomas C.

AU - Kilts, Clinton D.

AU - Nemeroff, Charles

AU - Mayberg, Helen S.

PY - 2014/6/21

Y1 - 2014/6/21

N2 - Background: Pharmacologic treatment options for posttraumatic stress disorder (PTSD) are limited in number and effectiveness. Medications currently in use to treat PTSD were originally approved based on their efficacy in other disorders, such as major depression. Substantial research in PTSD suggests that increased activity of corticotropin releasing hormone (CRH)-containing circuits are involved in the pathophysiology of the disease. This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD.Methods/design: Currently untreated adult women, ages 18 to 65 years, with a primary psychiatric diagnosis of PTSD of at least 3 months' duration, are being enrolled in a parallel-group, double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of GSK561679, a novel CRHR1 receptor antagonist. GSK561679 (or matching placebo) is prescribed at a fixed dose of 350 mg nightly for six weeks. The primary trial hypothesis is that GSK561679 will reduce symptoms of PTSD, as measured by the Clinician-Administered PTSD Scale (CAPS), significantly more than placebo after six weeks of treatment. Putative biological markers of PTSD which may influence treatment response are measured prior to randomization and after five weeks' exposure to the study medication, including: fear conditioning and extinction using psychophysiological measures; variants of stress-related genes and gene expression profiles; and indices of HPA axis reactivity. In addition, the impact of PTSD and treatment on neuropsychological performance and functional capacity are assessed at baseline and after the fifth week of study medication. After completion of the six-week double blind treatment period, subjects enter a one-month follow-up period to monitor for sustained response and resolution of any adverse effects.Discussion: Considerable preclinical and human research supports the hypothesis that alterations in central nervous system CRH neuronal activity are a potential mediator of PTSD symptoms. This study is the first to assess the efficacy of a specific antagonist of a CRH receptor in the treatment of PTSD. Furthermore, the biological and neuropsychological measures included in this trial will substantially inform our understanding of the mechanisms of PTSD.Trial registration: Clinicaltrials.gov Identifier: NCT01018992.Registered 6 November 2009. First patient randomized 14 January 2010.

AB - Background: Pharmacologic treatment options for posttraumatic stress disorder (PTSD) are limited in number and effectiveness. Medications currently in use to treat PTSD were originally approved based on their efficacy in other disorders, such as major depression. Substantial research in PTSD suggests that increased activity of corticotropin releasing hormone (CRH)-containing circuits are involved in the pathophysiology of the disease. This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD.Methods/design: Currently untreated adult women, ages 18 to 65 years, with a primary psychiatric diagnosis of PTSD of at least 3 months' duration, are being enrolled in a parallel-group, double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of GSK561679, a novel CRHR1 receptor antagonist. GSK561679 (or matching placebo) is prescribed at a fixed dose of 350 mg nightly for six weeks. The primary trial hypothesis is that GSK561679 will reduce symptoms of PTSD, as measured by the Clinician-Administered PTSD Scale (CAPS), significantly more than placebo after six weeks of treatment. Putative biological markers of PTSD which may influence treatment response are measured prior to randomization and after five weeks' exposure to the study medication, including: fear conditioning and extinction using psychophysiological measures; variants of stress-related genes and gene expression profiles; and indices of HPA axis reactivity. In addition, the impact of PTSD and treatment on neuropsychological performance and functional capacity are assessed at baseline and after the fifth week of study medication. After completion of the six-week double blind treatment period, subjects enter a one-month follow-up period to monitor for sustained response and resolution of any adverse effects.Discussion: Considerable preclinical and human research supports the hypothesis that alterations in central nervous system CRH neuronal activity are a potential mediator of PTSD symptoms. This study is the first to assess the efficacy of a specific antagonist of a CRH receptor in the treatment of PTSD. Furthermore, the biological and neuropsychological measures included in this trial will substantially inform our understanding of the mechanisms of PTSD.Trial registration: Clinicaltrials.gov Identifier: NCT01018992.Registered 6 November 2009. First patient randomized 14 January 2010.

KW - Anxiety disorders

KW - Clinical Research Protocol

KW - CRH

KW - Drugs

KW - Fear conditioning

KW - Fear-potentiated startle

KW - HPA Axis

KW - Investigational

KW - Neuropsychological tests

KW - Placebo

KW - Psychophysiology

UR - http://www.scopus.com/inward/record.url?scp=84902702355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902702355&partnerID=8YFLogxK

U2 - 10.1186/1745-6215-15-240

DO - 10.1186/1745-6215-15-240

M3 - Article

C2 - 24950747

AN - SCOPUS:84902702355

VL - 15

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 240

ER -